Accoutumance orale rapide au Rifater®, association fixe de trois antituberculeux majeurs

Meybeck, Agnès; Just, N.; Nyunga, Martine; Quaden, C; H, Fallouh; Wallaert, B.

doi:10.1016/s0335-7457(02)00019-9

Cited by 6 publications

(5 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fourteen patients (10 females and four males), mean age 30.2 years (range 22-49) with severe refractory (n ¼ 13) and/or fistulizing (n ¼ 4) CD for a mean of 9.9 years (range [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19] were included in the induction of tolerance protocol ( Table 1).…”

Section: Patientsmentioning

confidence: 99%

“…Patients who have had an IgE-mediated anaphylactic reaction or an anaphylactoid reaction to a medication and who require continuation of that medication may undergo a desensitization procedure. Many publications have reported the success of the desensitization to ciprofloxacin, 10, 11 aminoside, 12 vancomycin, 12 antituberculous agents, [13][14][15][16] insulin 17,18 and allopurinol. 19,20 Interruptions of the therapy could result in resensitization and therefore would require repeated desensitization procedures prior to any subsequent drug infusions.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions

Duburque¹,

Lelong

Iacob

et al. 2006

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SUMMARY AimTo appraise the tolerance and efficacy of an induction of tolerance protocol to infliximab permitting the re-administration of the drug to patients with Crohn's disease having had infusion reactions requiring suspension of treatment. MethodsFourteen patients were included in the induction of tolerance protocol. Each infusion of infliximab (5 mg/kg) was divided into 11 escalating 15 min increments over a 3-h time period. The induction of tolerance procedure was repeated for subsequent infusions. ResultsTen patients (71.4%) received all the three infusions for the induction treatment. Nine (64.3%) had a significant response and six (48.8%) still benefited from infliximab infusions. Seven patients (50%) achieved a complete remission, after a mean of 2.5 (two to three) infusions. Four patients (28.6%) had no response and the protocol was stopped. Three patients (21.4%) experienced mild immediate hypersensitivity reactions, which were controlled, two patients (14.2%) experienced severe immediate hypersensitivity reactions, leading to interruption of the treatment and one patient developed a delayed hypersensitivity reaction. ConclusionOur induction of tolerance protocol allows some patients who have experienced severe or repetitive infusion reactions to infliximab to be safely retreated with the drug in a hospitalized setting, with a clinical response achieved in a majority of these patients.

show abstract

Section: Patientsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions

Duburque¹,

Lelong

Iacob

et al. 2006

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…This involves introducing increasing doses of antituberculosis drugs to achieve temporary tolerance to the drug responsible for hypersensitivity. Success rates for desensitization to anti-tuberculosis drugs are generally acceptable, with success rates approaching 82% for rifampicin and 75% for isoniazid in some series [17] [26] [27]. In addition, regular monitoring of patients during treatment is essential, as is the identification and management of other potential adverse effects of anti-tuberculosis drugs.…”

Section: Discussionmentioning

confidence: 99%

An Atypical Ovarian and Peritoneal Pelvic Tuberculosis Complicated by Toxidermia

Sarr,

Thioub,

Lawson

et al. 2023

CRCM

View full text Add to dashboard Cite

Background: Ovarian tuberculosis is a rare form of tuberculosis. Its clinical presentation mimics an ovarian tumor, leading to misdiagnosis. Proper treatment with anti-tuberculosis drugs can lead to a cure for the disease but can sometimes cause adverse effects that compromise therapeutic management. Observation: We report a 71-year-old female Senegalese patient who presented with a chronic abdominopelvic mass with an elevated Cancer Antigen 125 (CA125) level, raising the suspicion of an ovarian tumor. She underwent an exploratory laparotomy and the anatomopathological study confirmed the diagnosis of ovarian and peritoneal tuberculosis. After starting treatment with anti-tuberculosis drugs, she developed toxidermia in the form of generalized urticaria. Discontinuation of the four-drug therapy and separate reintroduction of anti-tuberculosis drugs led to the incrimination of rifampicin. Progress was then favorable on Isoniazid (H) pyrazinamide (Z) and Ethambutol (E). Conclusion: Ovarian tuberculosis should be suspected in the presence of an abdominopelvic mass in a woman living in an endemic area. The occurrence of adverse reactions to anti-tuberculosis treatment is not uncommon, hence the importance of regular monitoring.

show abstract

“…La tuberculose est un problème majeur de santé publique dans le monde, son traitement repose essentiellement sur une quadrithérapie: Isoniazide (INH), Rifampicine (RIF), Pyrazinamide (PZA), et Ethombutol (ETB). Même si les effets secondaires de ce traitement sont multiples, les réactions d'hypersensibilité allergique sont assez rares (5% des cas), elle sont plus fréquentes chez les terrains immunodéprimés par le VIH (25% des cas), les insuffisants hépatiques et rénaux, et en cas d'un traitement administré d'une façon intermittente [ 1 , 2 ]. Ormerod et al ont montré dans leur étude que ces réactions sont plus fréquentes chez les femmes que chez les hommes [ 2 – 4 ].…”

Section: Discussionunclassified

“…Le protocole de Demoly a été publié pour d'autres médicaments, il a débuté la désensibilisation par 1/1000000 de la dose thérapeutique. L'accoutumance aux formes combinées pose un problème d'identification du produit en cause, elle entraine fréquemment des effets indésirables, J Drira et A Meybeck ont rapporté un cas d'accoutumance rapide par voie orale au Rifater menée avec succès [ 1 – 9 ].…”

Section: Discussionunclassified

L’intérêt de l’accoutumance aux antituberculeux majeurs

Aniked¹,

Bakouh²,

Bourkadi³

2014

Pan Afr Med J

View full text Add to dashboard Cite

Les réactions d’ hypersensibilité aux antituberculeux sont relativement rares et graves par leur caractère imprévisible, elles conduisent généralement à l'arrêt ou au changement thérapeutique. Nous rapportons un cas d'hypersensibilité à trois antibacillaires majeurs (Isoniazide, Pyrazinamide, Ethombutol). Une accoutumance orale à ces trois médicaments a été réalisée permettant à la patiente de bénéficier d'un traitement antibacillaire optimal.

show abstract

Accoutumance orale rapide au Rifater®, association fixe de trois antituberculeux majeurs

Cited by 6 publications

References 3 publications

Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions

Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions

An Atypical Ovarian and Peritoneal Pelvic Tuberculosis Complicated by Toxidermia

L’intérêt de l’accoutumance aux antituberculeux majeurs

Contact Info

Product

Resources

About